Compare HXL & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HXL | IBRX |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 7.2B |
| IPO Year | 1994 | 2015 |
| Metric | HXL | IBRX |
|---|---|---|
| Price | $96.87 | $7.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $88.30 | $12.57 |
| AVG Volume (30 Days) | 879.8K | ★ 11.5M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,893,900,000.00 | $113,288,000.00 |
| Revenue This Year | $10.09 | $88.59 |
| Revenue Next Year | $12.33 | $131.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $56.20 | $1.95 |
| 52 Week High | $101.51 | $12.43 |
| Indicator | HXL | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 55.17 |
| Support Level | $81.10 | $6.69 |
| Resistance Level | $97.69 | $8.54 |
| Average True Range (ATR) | 3.24 | 0.44 |
| MACD | 0.14 | 0.08 |
| Stochastic Oscillator | 65.65 | 78.91 |
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use primarily in the commercial aerospace and defense markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engine nacelles, and other structures and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.